ZOMDF vs ZTS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ZTS is the larger of the two ($32.57B market cap): the incumbent the market prices for continued execution (12.58x forward earnings, beta 0.68). ZOMDF is the smaller challenger ($79.57M): more room to run, but more to prove. If you believe the upside is worth bigger swings, ZOMDF fits (beta 1.32). If you want the steadier ride, ZTS fits (beta 0.68).

ZOMDF vs ZTS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricZOMDFZTSWhat it tells you
Market cap$79.57M$32.57BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Beta1.320.68Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range13% of range18% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book0.779.89How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ZOMDF and ZTS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ZOMDF and ZTS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ZOMDF and ZTS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Zomedica (ZOMDF) do?

Zomedica Corp. is an Alberta-incorporated, Michigan-based animal-health company that sells therapeutic devices and point-of-care diagnostics to equine and companion-animal veterinarians. Its largest line is the PulseVet electrohydraulic shockwave system, acquired in 2021, which treats tendon, ligament, bone and wound conditions and earns recurring revenue from replacement applicators called trodes. It also sells Assisi pulsed electromagnetic devices, VETIGEL hemostatic gel, the TRUFORMA diagnostic platform, VETGuardian remote vital-signs monitoring and TRUVIEW digital cytology. A third segment, Development Services, began in the second half of 2025 and sells engineering, development and contract manufacturing work to outside partners. In September 2026 it announced a strategic partnership with Veterinary Study Groups (VMG) to bring its technologies to independent practices.

Full ZOMDF guide

What does Zoetis (ZTS) do?

Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.

Full ZTS guide

ZOMDF vs ZTS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ZOMDF drivers: PulseVet consumables and the installed base; TRUFORMA diagnostics and the Boehringer collaboration.
  • ZTS drivers: Leader in a structurally growing market; Innovation-driven franchises and pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. For ZTS, zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted more than one guidance cut in 2026; third-quarter companion-animal sales fell about 5%, analysts expect 2026 EPS of about $6.33, roughly 1% lower than 2025, and fourth-quarter consensus EPS of about $1.19 implies a decline of nearly 20% from a year earlier.

ZOMDF or ZTS: which should you pick?

If the story you believe is ZOMDF's (PulseVet consumables and the installed base), ZOMDF is the more direct way to own it; if it is ZTS's (Leader in a structurally growing market), ZTS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ZOMDF and ZTS guides.

ZOMDF vs ZTS: the full fundamentals

ZOMDF. Trailing revenue is derived from ~$32.0 million in 2025 plus ~$28.2 million in the first nine months of 2026, less ~$21.6 million in the first nine months of 2025. At ~$0.08 a share, the market value of ~$80 million is about ~2.1 times sales and below book value (Yahoo shows ~0.77 times book). Subtracting ~$40.9 million of liquidity leaves an enterprise value near ~$39 million, about ~1.0 times sales. Because the company is unprofitable, earnings-based multiples do not apply.

ZTS. Zoetis has long been valued as a high-quality, defensive-growth compounder at a premium price-to-earnings multiple, but after the 2026 guidance cuts and a roughly 36% year-to-date decline it traded near 14 times trailing and 13 times forward earnings as of November 20, 2026, closer to a value multiple than its history. The market is pricing in stalled companion-animal growth, softer Librela demand and trade-down by pet owners, against still-high margins and about $2 billion of annual free cash flow. The 13 covering analysts have a mean target near $89.69, and consensus expects 2026 EPS of about $6.33 and 2027 EPS of about $6.37, essentially flat.

Headline figures (approximate, November 2026): ZOMDF shows revenue (ttm) ~$38.7 million; Q3 2026 ~$9.9 million, up ~22%, net loss (ttm) ~$16 million; Q3 2026 ~$3.2 million (vs ~$6.1 million), gross margin (q3 2026) ~61%, market cap ~$80 million (~$0.08 a share, Nov 20, 2026); ZTS shows revenue (ttm) ~$9.5 billion; Q3 2026 down ~1% YoY, q3 2026 revenue / eps ~$2.39 billion / ~$1.75 (vs ~$1.51 est.), q3 2026 segment sales Companion animal ~$1.6 billion (down ~5%), livestock ~$797 million (up ~7%), operating / net margin (ttm) ~38% / ~26%.

The bottom line: ZOMDF vs ZTS

ZOMDF and ZTS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ZOMDF and ZTS exposure against your real portfolio. It is not an investment adviser.

Wondering how ZOMDF or ZTS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Zomedica

Ask Walnut's AI anything about ZOMDF and see how it fits what you own.

FAQ

What is the difference between ZOMDF and ZTS?

+

Zomedica Corp. Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ZOMDF or ZTS the better stock?

+

Neither is universally better. ZTS is the larger incumbent; ZOMDF is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ZOMDF or ZTS?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ZOMDF and ZTS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ZOMDF vs ZTS?

+

ZOMDF: The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. Cash and securities fell to ~$40.9 million at September 30, 2026 from ~$44.1 million in June as the company funded losses, and a slower burn reduction would shorten its runway. The share count is very large at ~980 million, so even small per-share price moves change the market value meaningfully, and any future equity raise at today's prices would dilute heavily. OTCQB trading usually means thinner liquidity, wider spreads and less analyst coverage than an exchange listing; no analysts publish estimates on Yahoo. Shareholders rejected the executive pay proposal at the June 2026 meeting, a sign of investor frustration, and the stock is down about 26% over the year to November 20, 2026. Commercially, PulseVet faces other shockwave and rehabilitation devices, TRUFORMA competes with much larger diagnostic suppliers, and Development Services revenue depends on a few project contracts and already dipped quarter over quarter. Finally, the 2025 impairments show that past acquisitions have not earned back what was paid for them. ZTS: Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted more than one guidance cut in 2026; third-quarter companion-animal sales fell about 5%, analysts expect 2026 EPS of about $6.33, roughly 1% lower than 2025, and fourth-quarter consensus EPS of about $1.19 implies a decline of nearly 20% from a year earlier. Management has also said it is reviewing which measures it guides on, so the February 2027 outlook is an open question. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. The stock already de-rated sharply in 2026 (down about 31% over one year and about 36% year to date to November 20), showing how a premium multiple can compress when growth stalls. The balance sheet carries about $9.3 billion of debt against about $1.5 billion of cash. It is a growth-oriented holding, not a deep-value or high-yield income stock.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ZOMDF or ZTS; figures are approximate and dated (as of November 2026). Verify current data before investing.